Summary
Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/physiological saline partition coefficient equalled 2.14 and 1.68, respectively), the cerebrovascular permeability-surface area product, PA, of vincristine in plasma was only 0.49 × 10−4 ml s−1 g−1 for parietal cerebral cortex, whereas that of vinblastine was too low for determination. These values are similar to those of water-soluble, poorly diffusible nonelectrolytes. The PAs were significantly higher in the absence of plasma protein, being 1.24 × 10−4 and 5.36 × 10−4 ml s−1 g−1, respectively. Even these values, determined by brain perfusion of protein-free buffer, were lower than would be expected from the lipophilicity of the agents. The results suggest that additional factors, such as steric hindrance and molecular charge distribution, related to the chemical and geometric structure and the large size of vincristine and vinblastine (molecular weight, 825 and 814 daltons, respectively) restrict their passage across the blood-brain barrier. As a consequence of their paradoxically low permeability at the blood-brain barrier and restrictive binding to plasma and blood constituents, doses of both agents that cause significant inhibition of extracerebral Walker 256 carcinosarcoma tumor implants in rat have no effect on tumor located in the brain.
Similar content being viewed by others
References
Affra D (1973) Vincristine therapy in malignant glioma recurrences. Neurochirurgia (Stuttg) 16: 189–198
Ames MM, Powis G, Kovach JS (1983) Pharmacokinetics of anti-cancer agents in humans. Elsevier, Amsterdam
Bender RA, Chabner B (1982) Tubulin binding agents. In: Chabner B (ed) Pharmacoligical principles of cancer treatment. WB Saunders, Philadelphia, p 256
Bender RA, Castle MC, Margileth DA, Oliverio VT (1977) The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 22: 430–438
Braham J, Sarova-Pinhas I, Goldhammer Y (1969) Glioma of the brain treated with intravenous vincristine sulfate. Neurochirurgia (Stuttg) 12: 195–200
Calabresi P, Parks E (1980) Antiproliferative agents and drugs used for immunosuppression. In: Goodman A, Gilman S (eds) The pharmacoligical basis of therapeutics. Macmillan, London
Carter SK, Bakowski MT, Hellman K (1987) Chemotherapy of cancer, 3rd edn. Wiley Medical, New York
Castle MC, Margileth DA, Oliverio VT (1976) Distribution and excretion of [3H]-vincristine in the rat and the dog. Cancer Res 36: 3684–3689
Cefalu WT, Pardridge WM (1985) Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. J Neurochem 45: 1954–1956
Chen T, Mealey J (1970) Microculture of human brain tumors. Cancer Chemother Rep 54: 9–14
Creasey WA (1979) The vinca alkaloids. In: Hahn FE (ed) Antibiotics, vol 2. Springer, Berlin, p 414
Dareer S, White V, Chen F, Mellet L, Hill D (1977) Distribution and metabolism of vincristine in mice, rats, dogs and monkeys. Cancer Treat Rep 61: 1269–1277
Donigian DW, Owellen RJ (1973) The interaction of vinblastine, vincristine and colchinine with serum proteins. Biochem Pharmacol 22: 2113–2119
Dorr R, Fritz W (1980) Cancer chemotherapy handbook. Kimpton, London
Finklestein J, Arima E, Byfield P, Byfield J, Fonkalsrud E (1973) Murine neuroblastoma: a model of human disease. Cancer Chemother Rep 57: 405–412
Finklestein J, Tittle K, Meshnik R, Weiner J (1975) Murine neuroblastoma: a further evaluation of C1300 model with single antitumor agents. Cancer Chemother Rep 59: 975–983
Gerzon K (1980) Dimeric catharathus alkaloids. In: Cassady JM, Douros JD (eds) Anticancer agents based on natural product models. Academic Press, New York, p 271–317
Greig NH (1984) Chemotherapy of brain metastases: current status. Cancer Treat. Rev 11: 157–180
Greig NH (1987) Optimizing drug delivery to brain tumors. Cancer Treat Rev 14: 1–28
Greig NH (1989) Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA (ed) Clinical impact of the blood-brain barrier and its manipulation: basic studies, vol 1. Plenum Press, New York, pp 311–367
Greig NH, Rapoport SI (1988) Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemother Pharmacol 21: 1–8
Greig NH, Jones H, Cavanagh J (1983) Blood-brain barrier integrity and host responses in experimental metastatic brain tumors. Clin Exp Metastasis 1: 229–246
Greig NH, Momma S, Sweeney DJ, Smith QR, Rapoport SI (1987) Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 47: 1571–1576
Greig NH, Sweeney DJ, Rapoport SI (1987) Melphalan concentration dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 32: 179–185
Hirano A, Zimmerman HM (1970) Some effects of vinblastine implantation in the cerebral white matter. Lab Invest 23: 358–367
Jackson DV, Bender RA (1979) Cytotoxic thresholds of vincristine in a murine and human leukemic cell line in vitro. Cancer Res 39: 4346–4351
Jackson DV, Castle MC, Bender RA (1978) Biliary excretion of vincristine. Clin Pharmacol Ther 24: 101–107
Jackson DV, Castle MC, Poplack DG, Bender RA (1980) Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates. Cancer Res 40: 722–724
Jackson DV, Sethi VS, Spurr CL, McWhorter JM (1981) Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 41: 1466–1468
Jackson DV, Sethi VS, Spurr CL, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, Castle M (1981) Pharmacokinetics of vincristine infusion. Cancer Treat Rep 65: 1043–1048
Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9: 103–130
King KL, Boder GB (1979) Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine and vindesine with their effects on cultured rat midbrain cells. Cancer Chemother Pharmacol 2: 239–242
Miller R (1966) Simultaneous statistical inferences. McGraw-Hill, New York, pp 76–81
Momma S, Aoyagi M, Rapoport SI, Smith QR (1971) Phenylalanine transport across the blood-brain barrier as studied with the in situ brain perfusion technique. J Neurochem 48: 1291–1300
Nelson RL, Dyke RW, Root MA (1980) Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 7: 17–24
Omiwa K, Hazama F, Mikawa H (1983) Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier. Neuropathol Appl Neurobiol 9: 345–354
Owellen RJ, Hartke CA, Hains FO (1977) Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597–2602
Owens G (1969) Intra-arterial chemotherapy of primary brain tumors. Ann NY Acad Sci 159: 603–607
Rosenstock J, Evans A, Schut L (1976) Response to vincristine of recurrent brain tumors in children. J Neurosurg 45: 135–140
Selvin MJ, Slaquet MJ (1986) Randomized trials in cancer: a critical review by sites. Raven Press, New York, p 15
Sethi VS, Thimmaiah KN (1985) Structural studies on the degradation products of vincristine dihydrogen sulfate. Cancer Res 45: 5386–5389
Sethi VS, Surratt P, Spurr CL (1984) Pharmacokinetics of vincristine, vinblastine and vindesine in rhesus monkeys. Cancer Chemother Pharmacol 12: 31–35
Shapiro W (1971) Studies on the chemotherapy of experimental brain tumors. Evaluation of CCNU, vincristine and 5FU. Natl Cancer Inst Monogr 46: 359–369
Smith QR, Takasato Y (1986) Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann NY Acad Sci 481: 186–201
Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid across the blood-brain barrier. J Neurochem 49: 1651–1658
Steele WH, King DJ, Barber HE, Hawksworth GM, Dawson AA, Petrie JC (1983) The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin’s disease. Eur J Clin Pharmacol 24: 683–687
Stein WD (1986) Simple diffusion across the membrane bilayer. In: Stein WD, Lieb WR (eds) Transport and diffusion across cell membranes. Academic Press, London, pp 69–107
Takasato Y, Rapoport SI, Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247: H484-H493
Thimmaiah KN, Sethi VS (1985) Chemical characterization of the degradation products of vinblastine dihydrogen sulfate. Cancer Res 45: 5382–5385
Thompson GL, Boder GB, Bromer WW, Grindey GB, Poore GA (1982) Ly 119863, a novel potent vincy analogue with unique biological properties. Proc Am Assoc Cancer Res 23: 201
Wenger R (1982) Chemistry of cyclosporin. In: White DJG (ed) Cyclosporin A. Elsevier, New York, p 20
Wu Y, Genka S, Shitara N, Wada T, Takakura K (1987) Effect of vincristine on human glioma cell line: flow cytometry analysis of DNA and bromodeoxyuridine. J Clin Exp Med (Jpn) 142: 777–778
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greig, N.H., Soncrant, T.T., Shetty, H.U. et al. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol 26, 263–268 (1990). https://doi.org/10.1007/BF02897227
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02897227